Does the Time of Day You Receive Immunotherapy Affect Survival? The Evidence Is Stronger Than You Think

By Dr. Lena Suhaila ND, FABNO

Checkpoint inhibitors have transformed the treatment of several advanced cancers. For patients with non-small cell lung cancer, melanoma, kidney cancer, and other malignancies, these drugs have extended survival in ways that were unimaginable two decades ago by releasing the immune system’s capacity to recognize and destroy cancer cells.

But a consistent and clinically important question has remained largely unaddressed: why do some patients respond dramatically while others do not, even when they receive the same drug at the same dose?

A growing body of evidence is pointing toward one underexamined variable, and it has nothing to do with which drug you are on or what your PD-L1 status is. It comes down to what time of day the infusion is given.

If you are currently receiving a checkpoint inhibitor or preparing to start one, this is worth understanding in detail.

Why the Immune System Has a Clock

The immune system does not operate on a flat line across the 24-hour day. It follows precise circadian rhythms governed by the body’s internal clock, determining when immune cells are most numerous, most active, and most responsive to therapeutic signals.

Circulating CD8 T cells, the primary immune cells targeted by checkpoint inhibitors, are cytotoxic lymphocytes, and they roughly double in number between early morning and early evening. This is worth paying attention to beyond timing alone. Your absolute lymphocyte count, which your doctor can see on a standard CBC with differential, gives a broader picture of the immune substrate your treatment is working with. If your overall lymphocyte pool is depleted going into treatment or drops significantly during treatment cycles, the specific CD8 compartment is likely compromised as well, and the checkpoint inhibitor has less to engage regardless of what time it is delivered. It is worth asking your oncology team to track this number longitudinally across your treatment, not just at baseline.

One more variable that rarely gets discussed with patients directly: corticosteroids. Steroids are commonly prescribed alongside immunotherapy, sometimes to manage immune-related side effects, sometimes as part of an antiemetic protocol, sometimes for other reasons entirely. The problem is that corticosteroids are broadly immunosuppressive. They dampen lymphocyte activity, which is precisely the biological machinery checkpoint inhibitors are designed to activate. If you are on steroids concurrently with immunotherapy, even short courses, it is a conversation worth having with your team about timing, necessity, and whether alternatives exist. This does not mean steroids are never appropriate in this context. It means the tradeoff deserves to be named out loud.

The expression of PD-1 and PD-L1, the very proteins these drugs are designed to block, also fluctuates throughout the day. Preclinical studies have demonstrated that diurnal expression of PD-1 on tumor-associated macrophages underlies the dosing-time-dependent antitumor effects of PD-1/PD-L1 inhibitors. Delivering a checkpoint inhibitor when these targets are most biologically active is not a minor detail. It may be a significant determinant of whether the drug achieves its intended effect.

This field is called chronoimmunotherapy, and the clinical evidence for its relevance has been accumulating steadily across multiple cancer types and across three continents. What started as a compelling retrospective observation has now been tested in a randomized controlled trial.

The Phase III Randomized Trial: Non-Small Cell Lung Cancer, ASCO 2025

The most rigorous evidence to date comes from a phase III randomized controlled trial presented at the 2025 ASCO Annual Meeting. A prospective randomized trial was conducted, and its findings are difficult to dismiss.

The trial enrolled 210 patients with stage IV NSCLC who were randomized to receive immunochemotherapy either before or after 3 PM. Patients in the early infusion group had a median overall survival of 33 months, compared to 19.5 months in the late group, a hazard ratio for earlier death of 0.43. That is a difference of more than 13 months from a scheduling change alone, with no new drug, no new protocol, and no change to the treatment itself.

Objective response rates were also significantly higher: 75.2% in the early group versus 56.2% in the late group. These improvements held across age, sex, cancer stage, histology, PD-L1 status, and the specific checkpoint inhibitor used. Safety profiles were comparable between groups.

What is worth sitting with here is that PD-L1 status, the biomarker your oncologist uses to predict whether you will respond to a checkpoint inhibitor, did not modify the effect. Timing mattered regardless of what the biomarker said.

Metastatic Melanoma: The MEMOIR Study and What Followed

The melanoma data is among the most developed in this field and it is where the clinical conversation began in earnest. The MEMOIR study, published in The Lancet Oncology, found that in a propensity score-matched analysis of 146 patients, the risks of earlier disease progression or death were nearly twice as low in patients receiving less than 20% of their checkpoint inhibitor infusions after 4:30 PM, compared with those receiving 20% or more infusions after that time.

A subsequent retrospective study of patients with stage IV melanoma confirmed the pattern, finding that afternoon-predominant scheduling was consistently associated with shorter overall survival. The researchers noted that the mechanisms involve circadian variation in PD-1 expression on tumor-associated immune cells, which appears to be highest earlier in the day, precisely when checkpoint inhibitors have the most biological target to engage.

The Meta-Analysis: 13 Studies, 1,663 Patients, Five Cancer Types

Individual studies can be questioned. A well-conducted meta-analysis is considerably harder to set aside. A published meta-analysis pooled data from 13 retrospective studies across five cancer types, including non-small cell lung cancer, renal cell carcinoma, melanoma, urothelial cancer, and esophageal carcinoma, involving 1,663 patients. The pooled analysis found that patients receiving immunotherapy earlier in the day had a 50% lower risk of death compared to those treated later, with a hazard ratio of 0.50.

Progression-free survival showed a nearly identical benefit.

As of early 2025, the survival impact of time-of-day administration has been found to be remarkably consistent across seven different tumor types including non-small cell lung cancer, malignant melanoma, renal cell carcinoma, hepatocellular carcinoma, bladder, esophageal, and gastric cancers. The consistency across tumor types and geographies is what elevates this beyond an interesting anomaly into a clinically important signal.

What This Means for You Right Now

No formal clinical guidelines yet specify infusion timing as a standard consideration in immunotherapy scheduling. That will take time. But the weight of evidence has reached the point where this is no longer a fringe question. It is being asked at major academic oncology centers and presented on the main stage at ASCO.

If you are currently receiving a checkpoint inhibitor and have any flexibility in scheduling, you are entitled to ask your oncology team directly about completing your infusion before 3 PM. It requires no change to your drug, your dose, or your care plan. It is a scheduling preference with a meaningful and growing biological rationale, and if your oncology team is not yet familiar with this literature, the citations at the bottom of this article are a reasonable place to start that conversation.

Why the State of Your Internal Biology Matters Here

Here is where I want to bring this into the framework I work within, because this research does not exist in isolation from the broader question of what kind of internal environment you are bringing into that infusion chair.

The suprachiasmatic nucleus in the hypothalamus, the brain’s master internal clock, governs almost everything from when you repair cells, to when your hormones are released, to when your immune system is at its sharpest. When that clock is disrupted by chronic stress, poor or irregular sleep, disordered eating patterns, or sustained nervous system dysregulation, the downstream consequences affect the same biological machinery this research is measuring.

The state of your gut microbiome is also part of this picture. The research connecting microbiome diversity to immunotherapy response is compelling in its own right, and if you have not yet read what the science says about that connection, it is worth your time.

A patient whose circadian biology is well-supported is not the same patient as one who is sleeping poorly, eating at erratic hours, and running on a chronically activated stress response. The studies showing improved survival with morning infusions are working with patients whose internal clocks are presumably functional enough to matter. If yours is significantly disrupted, the timing advantage may be less pronounced, which means that supporting your terrain is not separate from supporting your treatment response. Given what this research is showing, the two are directly connected.

If you want a deeper look at all the variables that determine whether your biology is positioned to respond to immunotherapy, including your immune cell populations, your nutrient status, your genetics, and how to monitor whether your treatment is actually working, I have written about that in detail and it is worth reading alongside this article.

Researchers are now asking whether your individual biology, specifically whether you are naturally a morning or evening person, should influence when your infusion is scheduled. Consistent sleep and wake timing, strategic light exposure, meal timing aligned with your biological rhythms, and nervous system regulation through polyvagal-informed approaches all reinforce your body’s internal clock and strengthen the conditions this research depends on.

The field of chronoimmunotherapy is adding precise, measurable evidence to something integrative oncology has understood for a long time: your body has a rhythm, and working with that rhythm is not a soft preference. The biology behind it is real and increasingly well-documented.

Working at This Intersection

If you are receiving immunotherapy and want support in optimizing your terrain, your circadian biology, sleep architecture, metabolic health, and your body’s capacity to respond to treatment, this is exactly the intersection I work at. Integrative oncology is not about replacing your oncology team. It is about bringing a level of biological precision to the conditions in which your treatment is delivered, and asking the questions that the standard oncology appointment rarely has time to ask.

The research is clear that when matters. The question worth asking next is what is the state of the internal environment in which that timing operates.

If you are ready to explore that seriously, I would welcome the conversation.

Dr. Lena Suhaila is a naturopathic oncologist and the founder of Naturally Well Within. To learn more about her work, visit her About page.